Data protection Impressum

Personalized Medicine

Researchers from the Francis Crick Institute and Bern-based AlveoliX have developed the first human lung-on-chip model built entirely from genetically identical cells, opening new perspectives for personalised respiratory disease research.

AlveoliX contributes to first lung-on-chip model using genetically identical human cells

19 January 2026

Geneva-based biotech start-up FluoSphera has raised CHF 1.15 million to expand its human-relevant preclinical testing platform, supporting the shift toward more predictive and non-animal drug development models.

FluoSphera raises CHF 1.15 million to scale human-based preclinical drug testing

19 January 2026

Neurotechnology company ONWARD Medical extends its cash runway through 2026 and prepares to expand commercialization and clinical development of its ARC Therapy systems.

ONWARD Medical raises over EUR 50 million to advance spinal cord therapies

27 October 2025

HemostOD has raised CHF 4.3 million in a Seed-extension round to accelerate the industrialization of its donor-free, off-the-shelf human blood platelets. The new funding marks a key milestone for the EPFL spin-off as it transitions from proof-of-concept to large-scale manufacturing.

HemostOD raises CHF 4.3 million to scale production of universal blood platelets

6 October 2025

Geneva-based Multiwave Technologies has secured CHF 3.6 million to accelerate regulatory approval of its portable MRI device and establish a new assembly facility in the United States.

Multiwave raises CHF 3.6 million and opens US operations in Boston

1 October 2025

Geneva-based EarlySight has raised an additional CHF 3.1 million, bringing its seed financing round to CHF 6.1 million, to launch its next-generation product and advance U.S. approval.

Retinal imaging specialist EarlySight raises CHF 3.1 million to accelerate global growth

10 September 2025

Top Stories Western Switzerland

Top Stories from Western Switzerland (August 2025)

1 September 2025

Oculis expands its loan facility with BlackRock to CHF 100 million, extending its financial runway and supporting late-stage clinical trials.

Oculis secures up to CHF 100 million in expanded loan facility with BlackRock

5 August 2025

Geneva-based biotech Stalicla secures funding to advance precision medicine programs for autism and substance use disorders.

Addex Therapeutics leads CHF 2 million investment in Stalicla

14 July 2025

Biotech KYLYS Aesthetics has raised CHF 1 million to advance clinical development of its next-generation hyaluronic acid medical devices for regenerative aesthetic medicine.

Geneva-based KYLYS raises CHF 1 million to advance regenerative aesthetic medicine

23 June 2025

1 2 3 4 5 … 18